{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:49:14Z","timestamp":1771649354928,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T00:00:00Z","timestamp":1544572800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s10620-018-5381-0","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T05:31:46Z","timestamp":1544592706000},"page":"875-879","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Usefulness of Thiopurine Monotherapy for Crohn\u2019s Disease in the Era of Biologics: A Long-Term Single-Center Experience"],"prefix":"10.1007","volume":"64","author":[{"given":"Cristina","family":"Su\u00e1rez Ferrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yago","family":"Gonz\u00e1lez-Lama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Gonz\u00e1lez-Partida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Calvo Moya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Vera Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Matallana Royo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Arevalo Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Abreu Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,12]]},"reference":[{"key":"5381_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomollon","year":"2017","unstructured":"Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s Disease 2016: part 1: diagnosis and medical management. J Crohn\u2019s Colitis. 2017;11:3\u201325.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5381_CR2","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","volume":"19","author":"M Chaparro","year":"2013","unstructured":"Chaparro M, Ordas I, Cabre E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19:1404\u20131410.","journal-title":"Inflamm Bowel Dis"},{"key":"5381_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/ecco-jcc\/jjv188","volume":"10","author":"N Teich","year":"2016","unstructured":"Teich N, Mohl W, Bokemeyer B, et al. Azathioprine-induced acute pancreatitis in patients with inflammatory bowel diseases\u2014a prospective study on incidence and severity. J Crohn\u2019s Colitis. 2016;10:61\u201368.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5381_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","volume":"6","author":"L Peyrin-Biroulet","year":"2008","unstructured":"Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in\u00a0Crohn\u2019s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6:644\u2013653. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2008.03.014\n                    \n                  .","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5381_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.crohns.2013.04.006","volume":"8","author":"F Magro","year":"2014","unstructured":"Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohn\u2019s Colitis. 2014;8:31\u201344.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5381_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/pds.3621","volume":"23","author":"F Beigel","year":"2014","unstructured":"Beigel F, Steinborn A, Schnitzler F, et al. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf. 2014;23:735\u2013744.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5381_CR7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","volume":"145","author":"J Panes","year":"2013","unstructured":"Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn\u2019s disease. Gastroenterology. 2013;145:766\u2013774.","journal-title":"Gastroenterology"},{"key":"5381_CR8","doi-asserted-by":"publisher","first-page":"758-65.e2","DOI":"10.1053\/j.gastro.2013.04.048","volume":"145","author":"J Cosnes","year":"2013","unstructured":"Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn\u2019s Disease: a randomized controlled trial. Gastroenterology. 2013;145:758-65.e2. (quiz e14\u20135).","journal-title":"Gastroenterology"},{"key":"5381_CR9","first-page":"Cd000067","volume":"10","author":"N Chande","year":"2015","unstructured":"Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2015;10:Cd000067.","journal-title":"Cochrane Database Syst Rev"},{"key":"5381_CR10","first-page":"915","volume":"10","author":"G Pineton de Chambrun","year":"2016","unstructured":"Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Exp Rev Gastroenterol Hepatol. 2016;10:915\u2013927.","journal-title":"Exp Rev Gastroenterol Hepatol"},{"key":"5381_CR11","first-page":"459","volume":"106","author":"Y Gonzalez-Lama","year":"2014","unstructured":"Gonzalez-Lama Y, Suarez CJ, Blazquez I, et al. Mucosal healing in Crohn\u2019s disease: relevance and controversies in real life clinical practice. Revista Espanola de Enfermedades Digestivas. 2014;106:459\u2013466.","journal-title":"Revista Espanola de Enfermedades Digestivas"},{"key":"5381_CR12","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.crohns.2014.02.021","volume":"8","author":"WJ Sandborn","year":"2014","unstructured":"Sandborn WJ, Hanauer S, Van Assche G, et al. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohn\u2019s Colitis. 2014;8:927\u2013935.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5381_CR13","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.3748\/wjg.v21.i25.7795","volume":"21","author":"GW Moran","year":"2015","unstructured":"Moran GW, Dubeau MF, Kaplan GG, et al. Clinical predictors of thiopurine-related adverse events in Crohn\u2019s disease. World J Gastroenterol. 2015;21:7795\u20137804.","journal-title":"World J Gastroenterol"},{"key":"5381_CR14","doi-asserted-by":"publisher","first-page":"e1513","DOI":"10.1097\/MD.0000000000001513","volume":"94","author":"Y Qiu","year":"2015","unstructured":"Qiu Y, Mao R, Zhang SH, et al. Safety profile of thiopurines in crohn disease: analysis of 893 patient-years follow-up in a Southern China cohort. Medicine. 2015;94:e1513.","journal-title":"Medicine"},{"key":"5381_CR15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1365-2036.2005.02636.x","volume":"22","author":"G Bastida","year":"2005","unstructured":"Bastida G, Nos P, Aguas M, et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:775\u2013782.","journal-title":"Aliment Pharmacol Ther"},{"key":"5381_CR16","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/ibd.20160","volume":"13","author":"JP Gisbert","year":"2007","unstructured":"Gisbert JP, Luna M, Gonzalez-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007;13:1106\u20131114.","journal-title":"Inflamm Bowel Dis"},{"key":"5381_CR17","first-page":"79","volume":"108","author":"C Suarez Ferrer","year":"2016","unstructured":"Suarez Ferrer C, Llop Herrera E, Calvo Moya M, et al. Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease. Revista Espanola de Enfermedades Digestivas. 2016;108:79\u201383.","journal-title":"Revista Espanola de Enfermedades Digestivas"},{"key":"5381_CR18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","volume":"103","author":"JP Gisbert","year":"2008","unstructured":"Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008;103:1783\u20131800.","journal-title":"Am J Gastroenterol"},{"key":"5381_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1136\/flgastro-2015-100681","volume":"7","author":"Y Gonz\u00e1lez-Lama","year":"2016","unstructured":"Gonz\u00e1lez-Lama Y, Gisbert JP. Monitoring thiopurine metabolites in inflammatory bowel disease. Frontline Gastroenterol. 2016;7:301\u2013307.","journal-title":"Frontline Gastroenterol"},{"key":"5381_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1365-2036.2008.03746.x","volume":"28","author":"F Bermejo","year":"2008","unstructured":"Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28:623\u2013628.","journal-title":"Aliment Pharmacol Ther"},{"key":"5381_CR21","doi-asserted-by":"publisher","first-page":"847-58.e4","DOI":"10.1016\/j.cgh.2014.05.015","volume":"13","author":"DS Kotlyar","year":"2015","unstructured":"Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol. 2015;13:847-58.e4. (quiz e48\u201350).","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5381_CR22","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ibd.22977","volume":"19","author":"P Cruz De","year":"2013","unstructured":"De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn\u2019s disease: a systematic review. Inflamm Bowel Dis. 2013;19:429\u2013444.","journal-title":"Inflamm Bowel Dis"},{"key":"5381_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","volume":"63","author":"L Peyrin-Biroulet","year":"2014","unstructured":"Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial. Gut. 2014;63:88\u201395.","journal-title":"Gut"},{"key":"5381_CR24","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/apt.12743","volume":"39","author":"GR Jones","year":"2014","unstructured":"Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J. Systematic review: the use of thiopurines or anti-TNF in post-operative Crohn\u2019s disease maintenance\u2014progress and prospects. Aliment Pharmacol Ther. 2014;39:1253\u20131265.","journal-title":"Aliment Pharmacol Ther"},{"key":"5381_CR25","first-page":"Cd010233","volume":"8","author":"M Gordon","year":"2014","unstructured":"Gordon M, Taylor K, Akobeng AK, Thomas AG. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2014;8:Cd010233.","journal-title":"Cochrane Database Syst Rev"},{"key":"5381_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.crohns.2013.11.020","volume":"8","author":"F Magro","year":"2014","unstructured":"Magro F, Santos-Antunes J, Vilas-Boas F, et al. Crohn\u2019s disease outcome in patients under azathioprine: a tertiary referral center experience. J Crohn\u2019s Colitis. 2014;8:617\u2013625.","journal-title":"J Crohn\u2019s Colitis"},{"key":"5381_CR27","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease. N Engl J Med. 2010;362:1383\u20131395.","journal-title":"N Engl J Med"},{"key":"5381_CR28","first-page":"344-54.e5","volume":"148","author":"GS Hazlewood","year":"2015","unstructured":"Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis. Gastroenterology. 2015;148:344-54.e5. (quiz e14\u20135).","journal-title":"Gastroenterology"},{"key":"5381_CR29","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/MIB.0000000000000680","volume":"22","author":"ED Shah","year":"2016","unstructured":"Shah ED, Siegel CA, Chong K, Melmed GY. Evaluating study withdrawal among biologics and immunomodulators in treating ulcerative colitis: a meta-analysis of controlled clinical trials. Inflamm Bowel Dis. 2016;22:933\u2013939.","journal-title":"Inflamm Bowel Dis"},{"key":"5381_CR30","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2013.441","volume":"109","author":"GR Lichtenstein","year":"2014","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn\u2019s disease: results from the TREAT registry. Am J Gastroenterol. 2014;109:212\u2013223.","journal-title":"Am J Gastroenterol"},{"key":"5381_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/apt.12624","volume":"39","author":"CJ Williams","year":"2014","unstructured":"Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447\u2013458.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5381-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5381-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5381-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:17:14Z","timestamp":1576109834000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5381-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,12]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["5381"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5381-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,12]]},"assertion":[{"value":"20 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}